This study suggests CD73+ sEVs derived from tumor cells contribute to immunosuppression and are a potential predictor of anti-PD-1 responses for immune checkpoint therapy in HNSCC, defining hot vs. cold tumors and responders vs. non-responders. The gene discussed is NT5E; the disease is head and neck squamous cell carcinoma.